Avalon GloboCare Forms Strategic Partnership With Weill Cornell Medical College to Co-develop Technologies & Bio-production of CAR-T Therapy

Avalon GloboCare Corp. recently announced the company has formed a strategic partnership with Weill Cornell’s cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering headed by Dr. Yen-Michael Hsu. This strategic partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards. This strategic partnership will enable Avalon GloboCare to implement the resulting laboratory infrastructure and clinical plans in China and the US.

This partnership also includes a CAR-T education program to support and foster collaborative research and training programs for scientists and clinicians between Weill Cornell and Hebei Yanda LuDaopei Hospital, which is Avalon GloboCare’s main affiliated clinical facility as well as the world’s single largest medical institution in CAR-T therapy.

“This strategic partnership will synergize Weill Cornell’s world-class cGMP cellular therapy facility and our immense clinical resources at the LuDaopei hospital network to accelerate innovative CAR-T technology development, standardization in bio-manufacturing process, as well as knowledge exchange in CAR-T and other cellular therapies. Recently, we announced that Avalon formed a new wholly owned US subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to our proprietary CAR-T technologies. This new subsidiary is designed to integrate and optimize our global scientific and clinical resources, which will be instrumental as we advance this partnership with Weill Cornell,” said Dr. David Jin, CEO and President of Avalon GloboCare Corp. and the recently established CAR-T focused subsidiary Avactis Biosciences, Inc. “We are very proud to initiate this endeavor with an overarching goal of integrating premium research and clinical resources worldwide to provide standardized, safer, and more effective CAR-T therapy,” added Dr. Jin.

 Avalon GloboCare Corp. is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely Avalon Cell and Avalon Rehab. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients’ growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its US subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon will further establish its leading roles in the fields of CAR-T therapy, liquid biopsy, precision medicine, and regenerative medicine. For more information, visit http://www.avalon-globocare.com/index.html.